$メソブラスト (MESO.US)$Mesoblast (MESO) has released an update. Mesoblast Limited has resubmitted a Biologics License Application (BLA) to the FDA for Ryoncil®, aiming to treat children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD). The resubmission, buoyed by promising Phase 3 study results demonstrating significant survival benefits, could meet an urgent need for effective treatment in this patient group, as current survival outcomes are poor and no FDA-approved treatm...
$メソブラスト (MESO.US)$which is developing off-the-shelf cellular medicines for life-threatening inflammatory conditions, is planning to file a Biologics License Application for Ryoncil with the FDA next week.
Aariya : ほぼ完成しているか、すでに完了しているがまだ公開されていない可能性があります